title: Consensus statement: cardiovascular safety profile of triptans (5-HT agonists) in the acute treatment of migraine.
abstract: BACKGROUND
  Health care providers frequently cite concerns about cardiovascular safety of the triptans as a barrier to their use. In 2002, the American Headache Society convened the Triptan Cardiovascular Safety Expert Panel to evaluate the evidence on triptan-associated cardiovascular risk and to formulate consensus recommendations for making informed decisions for their use in patients with migraine.
  
  
  OBJECTIVE
  To summarize the evidence reviewed by the Triptan Cardiovascular Safety Expert Panel and their recommendations for the use of triptans in clinical practice.
  
  
  METHODS
  The Triptan Cardiovascular Safety Expert Panel was composed of a multidisciplinary group of experts in neurology, primary care, cardiology, pharmacology, women's health, and epidemiology.
  
  
  METHODS
  An exhaustive search of the relevant published literature was reviewed by each panel member in preparation for an open roundtable meeting. Pertinent issues (eg, cardiovascular pharmacology of triptans, epidemiology of cardiovascular disease, cardiovascular risk assessment, migraine) were presented as a prelude to group discussion and formulation of consensus conclusions and recommendations. Follow-up meetings were held by telephone.
  
  
  CONCLUSIONS
  (1) Most of the data on triptans are derived from patients without known coronary artery disease. (2) Chest symptoms occurring during use of triptans are generally nonserious and are not explained by ischemia. (3) The incidence of serious cardiovascular events with triptans in both clinical trials and clinical practice appears to be extremely low. (4) The cardiovascular risk-benefit profile of triptans favors their use in the absence of contraindications.
authors.affiliation: Department of Neurology, Mayo Clinic Scottsdale, AZ 85259, USA.
authors.forename: David
authors.initials: D
authors.lastname: Dodick
authors.forename: Richard B
authors.initials: RB
authors.lastname: Lipton
authors.forename: Vincent
authors.initials: V
authors.lastname: Martin
authors.forename: Vasilios
authors.initials: V
authors.lastname: Papademetriou
authors.forename: Wayne
authors.initials: W
authors.lastname: Rosamond
authors.forename: Antoinette
authors.initials: A
authors.lastname: MaassenVanDenBrink
authors.forename: Hassan
authors.initials: H
authors.lastname: Loutfi
authors.forename: K Michael
authors.initials: KM
authors.lastname: Welch
authors.forename: Peter J
authors.initials: PJ
authors.lastname: Goadsby
authors.forename: Steven
authors.initials: S
authors.lastname: Hahn
authors.forename: Susan
authors.initials: S
authors.lastname: Hutchinson
authors.forename: David
authors.initials: D
authors.lastname: Matchar
authors.forename: Stephen
authors.initials: S
authors.lastname: Silberstein
authors.forename: Timothy R
authors.initials: TR
authors.lastname: Smith
authors.forename: R Allan
authors.initials: RA
authors.lastname: Purdy
authors.forename: Jane
authors.initials: J
authors.lastname: Saiers
mesh_terms: D000208:Acute Disease; D002637:Chest Pain / Q000139:chemically induced; D003327:Coronary Disease / Q000139:chemically induced*; D019317:Evidence-Based Medicine; D006801:Humans; D008881:Migraine Disorders / Q000188:drug therapy*; D017366:Serotonin Receptor Agonists / Q000009:adverse effects* / Q000627:therapeutic use
chemical_list: D017366:Serotonin Receptor Agonists